Novonesis

The share should open slightly lower: Human Health fell by 8% vs. the expected 5.1%, and the guidance for the segment is lowered for the second time this year. The offset is an organic growth, i.e., excluding currency and acquisitions, of 6% vs. an expected 5.9% and a maintained guidance. See the full research report here:

Expect a positive opening. Novonesis raised its full-year growth guidance to 7-8% vs. the 6.9% analysts expected and announced its first share buyback of 1 BEUR. EUR. The counterweight is the largest division, Agriculture, Energy & Tech, which grew by 7% vs. the expected 8.6%.